In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while slashing the price …
While the biotech tape remains a challenging one, Maxim analysts remain positive on drug maker Keryx Biopharmaceuticals (NASDAQ:KERX) and gene-therapy-product maker bluebird bio Inc (NASDAQ:BLUE). Below …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced its financial results for …
Healthcare analysts weighed in today with positive reports on biopharmaceutical companies Relypsa Inc (NASDAQ:RLYP) and Keryx Biopharmaceuticals (NASDAQ:KERX). The analysts reflect on Relypsa’s positive results from Veltassa’s …
The 34th Annual JP Morgan Healthcare Conference kicked off today with several life science tools and diagnostic firms making presentations to investors and other attendees. Among …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that John P. Butler …
Analysts are eager to weigh in on biotech giant Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) after new earnings results and Lipocine Inc.
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results for …
Maxim’s healthcare analysts are weighing in on the Boston drug company Keryx Biopharmaceuticals (NASDAQ:KERX) and cancer drug discovery company Kite Pharma Inc (NASDAQ:KITE), following recent announcements. Keryx Biopharmaceuticals In a …
J.P.
